跳至主要内容
临床试验/DRKS00031372
DRKS00031372已完成不适用

Comprehensive characterization of psoriatic arthritis study - COMPACT

niversitätsklinikum Erlangen0 个研究点目标入组 92 人开始时间: 2023年4月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
92

研究概览

简要总结

Micro-structural progression is frequent in patients with PsA and despite treatment can affect approximately 25% of all patients within the first 3 years of follow-up. Higher disease activity over time was found to be the main determinant of bone damage, while therapy with b/tsDMARD slows bone deterioration. Thus, these data help to emphasize the critical period for the initiation of early b/tsDMARD treatment in preventing microstructural progression in PsA.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1)Written informed consent
  • 2)Adult male or female subject; age =18
  • 3)Fulfillment of the CASPAR PsA criteria
  • 4)Number of swollen joints =2
  • 5)Disease duration < 5 years

排除标准

  • 1)Diagnosis of any other rheumatological/ immunological disease such as rheumatoid arthritis, SLE, PSS, MCTD, M. Behcet or M. Wegener
  • 2)Concomitant florid immune mediated disease such as autoimmune hepatitis that is untreated and/or requires immunosuppressive treatment.
  • 3)Nursing mother or pregnant woman

研究者

发起方
niversitätsklinikum Erlangen

相似试验